Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib
combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).